Lake Como 2|4 October 2011 - CHIMICA Oggi/Chemistry Today

SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER SPEAKER
ABSTRACT
BIOGRAPHY
Pietro Delogu
Pietro Delogu is a chemist who spent his professional life in industrial research. He started
working in the Research Centre Montedipe, the petrochemical division of Montedison,
located in Bollate, near Milano. For 15 years his interests were in the fi eld of process
thermodynamics and kinetics, applied to process modelling, mainly for petrochemical
processes.
From 1985 to 1987 he worked at the Donegani Institute of Novara, the Corporate
Research Centre of Montedison, organising a new Department of Chemical and Process
Technologies.
In 1987 his fi eld of activity changed: he was charged at fi rst of the direction
of the R&D Division of ACNA C.O., and after of the R&D Division in Caffaro.
In this case the focus was on the dyes and fi ne chemical process
development, with special attention to agrochemicals.
Since 2004 he is the CEO of Serichim S.r.l., a Contract Research
Company operating in Torviscosa. Serichim is one of the fi rst
chemical research companies based in Italy, involved in
pharmaceutical and chemical process development.
His professional skills include process analysis and synthesis exploitation,
unit operation sizing, experimental team organisation.
During his activity he has published about 40 paper and patents. Pietro
Delogu teaches Industrial Chemistry at the Chemical Engineering Faculty of
Trieste.
Continuous fl ow processes: a multiproduct modular approach
Pietro Delogu
Serichim S.r.l. - Italy
The use of continuous processes for pharma products and intermediates is going to be more and more popular. Resistances to the
introduction of this “new” approach in the industrial practice are progressively overcome, as the valuable advantages in terms
of yields, product quality, safety and production costs become evident. As this technology is leaving the phase of its infancy,
innovation efforts should be devoted to increase operability and to better defi ne the criteria for qualifi cation of equipments and
validation of processes. Systems able to afford the continuous operation advantages, at the same time retaining the fl exibility
typical of the batch plants have to be designed and offered to the pharma industry.
Our communication discusses two topics: fi rst, how scaling up can be carried out in order to guarantee results independent
of the reactor size for the plant reaction section (when a conventional reaction system, based on plug fl ow reactors, is used);
second, a typical sequence of unit operations, able to effect the production of several APIs, is presented and proposed as a
continuous multiproduct unit. The multiproduct plant approach should be considered a very interesting requisite in order to
allow productions in campaigns based on continuous processes.
10
Lake Como
2|4 October 2011